UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

Current Report

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

September 10, 2013

--------------------------------------------

Date of Report (Date of earliest event reported) 

ELITE PHARMACEUTICALS INC.

--------------------------------------------------------

(Exact name of registrant as specified in its charter)

165 Ludlow Avenue, Northvale NJ 07647

------------------------------------------------------------------

(Address of principal executive offices)

(201) 750-2646

---------------------------

(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report)

        Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

On September 10, 2012, Epic Investments exercised the remaining Series E Convertible Preferred Stock. Pursuant to the terms of the Series E Convertible Preferred Stock, 65,843,621 shares of common stock were issued to Epic Investments upon the conversion.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.